6130 - Morquio Syndrome: Drugs (Answered)

Greg Mulholland
To ask the Secretary of State for Health, what assessment he has made of the compatibility of NHS England's announcement on 2 July 2015 on a final funding decision on Vimizim with the EU directive on transparency of measures regulating the prices of medicinal products for human use.

George Freeman

The Department is responsible for determining the price of medicinal products. The Department’s procedures for determining price comply with the requirements of the EU Directive on the transparency of measures regulating the prices of medicinal products. The Biomarin product Vimizim (elosulfase alfa) is currently being evaluated by the National Institute for Health and Care Excellence as part of its Highly Specialised Technologies programme. In the meantime, NHS England has defined a draft commissioning policy for elosulfase alpha for Mucopolysaccharidosis IV Type A on the basis of the clinical evidence of its effectiveness. No final funding decision has been made.